TipRanks
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
AVBP
ArriVent BioPharma, Inc.
RESEARCH TOOLSreports
Want to see AVBP full AI Analyst Report?

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

100 Followers
See the Price Targets and Ratings of:

AVBP Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
ArriVent
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$26.45
▼(-15.05% Downside)
Based on 12 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $26.45 with a high forecast of $50.00 and a low forecast of $15.00. The average price target represents a -15.05% change from the last price of $31.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","51":"$51","23.25":"$23.3","32.5":"$32.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.454545454545453,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,23.25,32.5,41.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.93,30.55076923076923,32.17153846153846,33.792307692307695,35.41307692307692,37.033846153846156,38.65461538461538,40.27538461538462,41.896153846153844,43.51692307692308,45.137692307692305,46.75846153846154,48.37923076923077,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.93,28.73958041958042,28.549160839160837,28.358741258741258,28.16832167832168,27.977902097902096,27.787482517482516,27.597062937062937,27.406643356643357,27.216223776223774,27.025804195804195,26.835384615384616,26.644965034965033,{"y":26.454545454545453,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.93,27.858461538461537,26.786923076923078,25.715384615384615,24.643846153846155,23.572307692307692,22.50076923076923,21.42923076923077,20.357692307692307,19.286153846153844,18.214615384615385,17.143076923076922,16.07153846153846,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.82,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.93,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$26.45Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
―
Buy
―
Reiterated
10/25/26
ArriVent cancer data support 'best-in-class' potential, says Clear StreetArriVent cancer data support 'best-in-class' potential, says Clear Street
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$20
Buy
-35.77%
Downside
Reiterated
10/23/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Merck & Company (NYSE: MRK)
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45→$29
Buy
-6.87%
Downside
Reiterated
10/20/26
ArriVent Biopharma price target lowered to $29 from $45 at B. RileyArriVent Biopharma price target lowered to $29 from $45 at B. Riley
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$27
Buy
-13.29%
Downside
Reiterated
10/13/26
ArriVent: Differentiated ADC Pipeline Drives Reiterated Buy Rating and Unchanged $27 Price Target
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$43→$15
Buy
-51.83%
Downside
Reiterated
10/06/26
Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45→$18
Buy
-42.20%
Downside
Assigned
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at GuggenheimArriVent Biopharma price target lowered to $18 from $45 at Guggenheim
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$45→$22
Buy
-29.35%
Downside
Reiterated
10/06/26
ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42→$29
Buy
-6.87%
Downside
Reiterated
10/06/26
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Jefferies Analyst forecast on AVBP
Kelly Shi
Jefferies
Jefferies
$45→$18
Buy
-42.20%
Downside
Reiterated
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at JefferiesArriVent Biopharma price target lowered to $18 from $45 at Jefferies
Truist Financial Analyst forecast on AVBP
Supawat Thongthip
Truist Financial
Truist Financial
$45→$18
Buy
-42.20%
Downside
Reiterated
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at TruistArriVent Biopharma price target lowered to $18 from $45 at Truist
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
60.57%
Upside
Reiterated
08/13/26
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Leerink Partners Analyst forecast on AVBP
Asthika Goonewardene
Leerink Partners
Leerink Partners
$45
Buy
44.51%
Upside
Reiterated
08/13/26
Truist Financial Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Clear Street Analyst forecast on AVBP
Kaveri Pohlman
Clear Street
Clear Street
―
Buy
―
Reiterated
10/25/26
ArriVent cancer data support 'best-in-class' potential, says Clear StreetArriVent cancer data support 'best-in-class' potential, says Clear Street
Citi Analyst forecast on AVBP
Yigal Nochomovitz
Citi
Citi
$20
Buy
-35.77%
Downside
Reiterated
10/23/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Merck & Company (NYSE: MRK)
B. Riley Securities Analyst forecast on AVBP
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$45→$29
Buy
-6.87%
Downside
Reiterated
10/20/26
ArriVent Biopharma price target lowered to $29 from $45 at B. RileyArriVent Biopharma price target lowered to $29 from $45 at B. Riley
H.C. Wainwright Analyst forecast on AVBP
Robert Burns
H.C. Wainwright
H.C. Wainwright
$27
Buy
-13.29%
Downside
Reiterated
10/13/26
ArriVent: Differentiated ADC Pipeline Drives Reiterated Buy Rating and Unchanged $27 Price Target
LifeSci Capital Analyst forecast on AVBP
Sam Slutsky
LifeSci Capital
LifeSci Capital
$43→$15
Buy
-51.83%
Downside
Reiterated
10/06/26
Analyst Maintains Buy on ArriVent Despite Trial Setback, Trims Price Target to $15 Ahead of Key ADC Data
Guggenheim Analyst forecast on AVBP
Michael Schmidt
Guggenheim
Guggenheim
$45→$18
Buy
-42.20%
Downside
Assigned
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at GuggenheimArriVent Biopharma price target lowered to $18 from $45 at Guggenheim
JonesTrading Analyst forecast on AVBP
Boris Peaker
JonesTrading
JonesTrading
$45→$22
Buy
-29.35%
Downside
Reiterated
10/06/26
ArriVent Retains Buy Rating as Analyst Sees Upside from Broader Pipeline Despite Trial Miss, Cutting Price Target to $22
BTIG Analyst forecast on AVBP
Jeet Mukherjee
BTIG
BTIG
$42→$29
Buy
-6.87%
Downside
Reiterated
10/06/26
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Jefferies Analyst forecast on AVBP
Kelly Shi
Jefferies
Jefferies
$45→$18
Buy
-42.20%
Downside
Reiterated
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at JefferiesArriVent Biopharma price target lowered to $18 from $45 at Jefferies
Truist Financial Analyst forecast on AVBP
Supawat Thongthip
Truist Financial
Truist Financial
$45→$18
Buy
-42.20%
Downside
Reiterated
10/06/26
ArriVent Biopharma price target lowered to $18 from $45 at TruistArriVent Biopharma price target lowered to $18 from $45 at Truist
Oppenheimer Analyst forecast on AVBP
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
60.57%
Upside
Reiterated
08/13/26
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Leerink Partners Analyst forecast on AVBP
Asthika Goonewardene
Leerink Partners
Leerink Partners
$45
Buy
44.51%
Upside
Reiterated
08/13/26
Truist Financial Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Cantor Fitzgerald Analyst forecast on AVBP
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/22/25
ArriVent Biopharma initiated with an Overweight at Cantor FitzgeraldArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VSTMVerastem
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

3 Months
Robert BurnsH.C. Wainwright
Success Rate
12/18 ratings generated profit
67%
Average Return
+8.83%
Copying Robert Burns's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.83% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
10/18 ratings generated profit
56%
Average Return
+10.80%
Copying Robert Burns's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +10.80% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
9/18 ratings generated profit
50%
Average Return
+10.34%
Copying Robert Burns's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +10.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
6
5
6
10
Buy
12
14
12
10
15
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
20
17
16
25
In the current month, AVBP has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 26.45.
Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$1.05 with a range of -$1.16 to -$1.00. The previous quarter’s EPS was -$1.05. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s earnings estimate for AVBP is -$1.05 with a range of -$1.16 to -$1.00. The previous quarter’s EPS was -$1.05. AVBP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.
Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AVBP has Performed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 26.45.
    What is AVBP’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for AVBP, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is AVBP a Buy, Sell or Hold?
        ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
          What is ArriVent BioPharma, Inc.’s price target?
          The average price target for ArriVent BioPharma, Inc. is 26.45. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $50.00 ,the lowest forecast is $15.00. The average price target represents -15.05% Decrease from the current price of $31.14.
            What do analysts say about ArriVent BioPharma, Inc.?
            ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of AVBP?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.